ISB News

Spotlight: Alison Paquette, Research Scientist

Congratulations to Alison Paquette who recently was promoted to Research Scientist in the Price Lab. Alison received her PhD in Experimental and Molecular Medicine at the Geisel School of Medicine at Dartmouth. She is interested in identifying molecular biomarkers that may predict preterm birth and adverse neonatal outcomes such as preeclampsia. “Pregnancy complications are not very well understood, and we are amongst the only labs really taking a systems biology approach to this kind of research,” Alison explains. “Complications from pregnancy affect the delivery process as well as potentially cause long-term consequences for the child.”  Alison’s supervisor, Dr. Nathan Price, commented: “She is one of the clearest thinkers and fastest writers I’ve ever worked with, and has shown this by completing the research and writing for many papers and (now funded!) grant proposals based on her work.”

Recent Articles

  • Timing is Everything: ISB Study Finds Link Between Bowel Movement Frequency and Overall Health

    Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.

  • Wei Wei, PhD

    Dr. Wei Wei Promoted to Associate Professor

    Wei Wei, PhD – an accomplished cancer researcher with expertise in biotechnology and cancer systems biology – has been promoted to ISB associate professor. The Wei Lab focuses on understanding how cancer cells adapt to therapeutic treatment to foster therapy resistance by coordinating their internal molecular machinery and how these adaptive changes evolve within diverse tumors influenced by the tumor microenvironment. 

  • Drs. Nitin Baliga and James Park

    How Glioblastoma Resists Treatment – and Ways to Prevent It

    Glioblastoma is one of the deadliest and most aggressive forms of primary brain cancer in adults and is known for its ability to resist treatment and to recur. ISB researchers have made breakthrough discoveries in understanding the mechanisms behind acquired resistance, focusing on a rare and stubborn group of cells within tumors called glioma stem-like cells.